Minimally Invasive Local Delivery of Cardiac Gene Therapy

Corami Biotech Inc., Memphis TN

Investigators

Abstract

PROJECT SUMMARY Cardiovascular diseases (CVD) are the leading cause of death in the United States, and current therapies are hindered by inefficient delivery methods, high systemic off-target exposure, and prohibitive costs, particularly for gene therapies. Corami Biotech’s platform combines a minimally invasive epicardial delivery device (EpiCor™) and a tunable hydrogel (GelCor™) which together localize therapeutic to the heart leading to significantly lower effective dose of gene therapy compared to systemic delivery while minimizing off-target expression.